<DOC>
	<DOCNO>NCT00832273</DOCNO>
	<brief_summary>VTI establish clinical protocol study effect ELAD® plus standard therapy compare standard therapy alone patient acute chronic ( AOCH ) ( VTI-201 , VTI-206 ) fulminant hepatic failure ( FHF ) ( VTI-202 ) acute alcoholic hepatitis ( AAH ) . However , liver failure ( LF ) patient qualify protocol may benefit ELAD use . In order accommodate physician request use ELAD LF patient qualify open Protocols , without need resort individual Emergency Use INDs case , VTI develop Treatment Protocol Cost Recovery provide expand access ELAD LF . This uncontrolled Treatment Protocol design provide expanded access ELAD subject LF assure sufficient data collect adequately monitor ELAD safety use set multiple center United States .</brief_summary>
	<brief_title>Use ELAD® Patients With Liver Failure Provide Expanded Access With Cost Recovery</brief_title>
	<detailed_description>ELAD® therapy design provide continuous liver support subject compromise liver function , allow time subject 's native liver regenerate healthy state , stabilize subject suitable donor organ find transplantation .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>1 . Weight ≥15 kg ; 2 . Age ≥10 ≤70 year ; 3 . MELD score ≥24 ; 4 . Documented liver failure ; 5 . Subject designated representative must willing sign Informed Consent Form specific study comply study requirement . 1 . Cerebral Perfusion Pressure ( CPP ) measure intracranial pressure ( ICP ) monitor . : 1 . Patients ≥ 18 yrs age Cerebral Perfusion Pressures ≤40 mm Hg one hour longer . 2 . Patients ≤18 yrs CPP ≤35 mm Hg one hour longer . 2 . Concomitant disease include chronic congestive heart failure , vascular disease , emphysema , AIDS , cancer , acute fattyliver disease , hepatitis due herpes virus , Wilson 's disease , BuddChiari syndrome ; 3 . Portal hypertension ; 4 . Liver dysfunction due trauma ; 5 . Hemorrhage irreversible brain death ; 6 . Platelet count &lt; 50,000/mm3 reduce &lt; 80,000/mm3 72 hour period ; 7 . Mean Arterial Pressures ( MAP ) ≤50 mm Hg one hour longer measure indwell arterial line , OR ; patient ≤18 year old whose MAP ≤40 mm Hg one hour longer ; 8 . Vasopressor support exceed 1.0 µg/kg/min alphaadrenergic agent one hour longer ; 9 . Clinical radiographic evidence stroke intracerebral bleeding ; 10 . Seizures uncontrolled medication ; 11 . Acute myocardial infarction base clinical and/or electrocardiographic evidence ; 12 . Lung disease define PaO2 ≤ 60mm Hg FiO2 ≥0.6 ; 13 . Pregnancy determine βhCG result ; 14 . ≤2 week postpartum ; 15 . Eligible open ELAD clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Expanded access ELAD® patient liver failure</keyword>
</DOC>